Versant Capital Management’s NEVRO CORP. NVRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,109
| Closed | -$6.48K | – | 2759 |
|
|
2025
Q1 | $6.48K | Buy |
1,109
+608
| +121% | +$3.2K | ﹤0.01% | 1922 |
|
|
2024
Q4 | $1.86K | Buy |
+501
| New | +$2.31K | ﹤0.01% | 2073 |
|
|
2024
Q1 | – | Sell |
-41
| Closed | -$882 | – | 1959 |
|
|
2023
Q4 | $882 | Buy |
41
+25
| +156% | +$446 | ﹤0.01% | 1550 |
|
|
2023
Q3 | $308 | Sell |
16
-30
| -65% | -$640 | ﹤0.01% | 1772 |
|
|
2023
Q2 | $1.17K | Buy |
+46
| New | +$1.33K | ﹤0.01% | 1544 |
|
|
2022
Q1 | – | Sell |
-3
| Closed | – | – | 1669 |
|
|
2021
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 1617 |
|
|
2021
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 1631 |
|
|
2021
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 1625 |
|
|
2021
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 1624 |
|
|
2020
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 1566 |
|
|
2020
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 1543 |
|
|
2020
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 1598 |
|
|
2020
Q1 | $0 | Buy |
+3
| New | +$361 | ﹤0.01% | 1742 |
|
Other funds holding NVRO
Versant Capital Management's NVRO Position: Q2 2025 in Review
Versant Capital Management sold out of NEVRO CORP. (NVRO) in Q2 2025, closing a stake of 1,109 shares — an estimated $6.48K sold.
Versant Capital Management first reported a position in NVRO in Q1 2020 and held it in 13 quarters. The position peaked at $6.48K in Q1 2025. 1 fund tracked by Wall St. Rank holds NVRO as of Q2 2025.
- Versant Capital Management reported no remaining NEVRO CORP. position as of Q2 2025 after selling out during the quarter.
- Versant Capital Management sold 1,109 NEVRO CORP. shares in Q2 2025, an estimated $6.48K.
- Versant Capital Management first reported a position in NEVRO CORP. in Q1 2020 and held it in 13 quarters.
- Versant Capital Management's NEVRO CORP. position peaked at $6.48K in Q1 2025.
- 1 fund tracked by Wall St. Rank held NEVRO CORP. as of Q2 2025.
Based on Versant Capital Management's 13F filing for Q2 2025, filed 7 Jul 2025.